US19240Q2012
US19240Q2012
Cogent Biosciences, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 5.38B EUR | 6.64B EUR | 6.57B EUR | 5.72B EUR |
Enterprise Value | 4.74B EUR | 6.7B EUR | 6.57B EUR | 5.64B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -27.88x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 11.38x | 12.47x | 10.82x | 8.99x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -12.26x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -3.46% | -4.66% | -4.36% | -3.48% |